RxDoctor Payments Data

Robert Dodds, MD

Urogynecology and Reconstructive Pelvic Surgery · Farmington Hills, MINPI 1952305765

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by AbbVie at 39.1% of the total. Reporting peaked in 2023 at $138 and has fallen 86.9% since, to $18 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in MI, where the typical reported total is $2,296.

$446in general payments, 2019–2025

Across 25 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$174
  • Axonics, Inc.$137
  • Astellas Pharma US Inc$68
  • Medtronic$33
  • Boston Scientific$18
  • Hologic Sales And Service, LLC$17

What the payments were for

  • Food & beverage$446100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)9$174
Axonics, Inc.8$137
Astellas Pharma US Inc4$68
Medtronic(2 entities)2$33
Boston Scientific1$18
Hologic Sales And Service, LLC1$17

How this compares

$446 in reported general payments places this provider in the 20th percentile of 33 urogynecology and reconstructive pelvic surgery providers in Michigan.

See all urogynecology and reconstructive pelvic surgery providers in Michigan

Medicare billing

Part B allowed, 2024
$71,196
Medicare patients
252
Services billed
977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron353$294,160
GemtesaVibegron257$257,989
Mirabegron ErMirabegron77$49,366
Estradiol154$9,926
Methenamine Hippurate36$3,026
DottiEstradiol19$2,658
Clobetasol Propionate42$2,368
Cimetidine21$2,356
Raloxifene Hcl14$1,141
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst107$1,057
Solifenacin Succinate17$592
Fluconazole85$527
Cephalexin64$512
Nystatin13$357
Amitriptyline Hcl28$320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$68$294,160353 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 33 urogynecology and reconstructive pelvic surgery providers in Michigan.

Other urogynecology and reconstructive pelvic surgery in Farmington Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →